• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Streamlining the Route of Administration of Monoclonal Antibody Therapies for Better Patient Outcomes in the NSCLC Population

by MM360 Staff | May 30, 2025 | Myeloma News

Source: Pharmacy Times articles A panelist discusses how the PALOMA-3 study demonstrated that subcutaneous amivantamab is noninferior to intravenous (IV) administration with significantly lower infusion-related reaction (IRR) rates (13% vs 66%), shorter administration...

Steroid-Refractory cGVHD: A Look at FDA-Approved Options

by MM360 Staff | May 30, 2025 | Myeloma News

Source: Pharmacy Times articles Panelists discuss how recent FDA approvals and evolving evidence for second-line treatments, including ruxolitinib, ibrutinib, and belumosudil, are reshaping chronic graft-vs-host disease (cGVHD) management by offering tailored,...

Tailoring Therapy: Weighing Evidence, Organ Involvement, and Route of Administration

by MM360 Staff | May 30, 2025 | Myeloma News

Source: Pharmacy Times articles Panelists discuss how factors such as patient preferences, disease severity, organ-specific involvement, and adverse effect profiles influence the selection of second-line therapies for steroid-refractory chronic graft-vs-host disease...

Personalized Care: How Do NSCLC Treatment Modifications and Patient-Specific Factors Impact Health Outcomes?

by MM360 Staff | May 30, 2025 | Myeloma News

Source: Pharmacy Times articles A panelist discusses how maintaining efficacy while preserving quality of life requires personalized approaches including dose adjustments or agent rotation based on specific toxicities, and how selecting the appropriate EGFR inhibitor...

Going with the Flow: Updates in Diabetes and Chronic Kidney Disease

by MM360 Staff | May 29, 2025 | Myeloma News

Source: Pharmacy Times articles CKD is a complication of diabetes. Emerging treatments aim to optimize management and reduce risks. Pharmacists are key in applying new evidence to clinical practice. Read More

ASCO 2025: Pre-Treatment DPYD Testing for Fluoropyrimidines Can Improve Patient Safety and Lower Cost

by MM360 Staff | May 29, 2025 | Myeloma News

Source: Pharmacy Times articles Two abstracts from ASCO demonstrate that pre-treatment DPYD genotyping improves the safety and cost-effectiveness of fluoropyrimidine chemotherapy, with oncology pharmacists playing a pivotal role in implementing and optimizing...
« Older Entries
Next Entries »

Recent Content

  • WHO grants nonproprietary name to ovarian cancer cell therapy
  • Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases
  • Carvykti label updated to include survival benefit data in myeloma
  • Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • Inflammatory markers from routine blood tests predict survival in multiple myeloma: a Systematic Review and meta-analysis
  • FDA approves ziftomenib to treat some relapsed leukemia patients
  • (no title)
  • The challenge of non-transplant eligible, newly diagnosed multiple myeloma
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT